---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Clinical trials questions"
description: "Clinical trials questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study 1489, Study 1490, Treatment-naive subgroups, Resistance, Study 1844, Study 1878, and 6 further topics. Questions: How does Biktarvy compare with abacavir/dolutegravir/lamivudine in adults starting HIV treatment (Study 1489)? How does Biktarvy compare with dolutegravir plus emtricitabine/tenofovir alafenamide in adults starting treatment (Study 1490)? Does Biktarvy work when starting treatment with a high viral load or low CD4 count? Has resistance to Biktarvy developed in clinical trials? 9 further questions follow. 13 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Clinical trials questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Study 1489

<a id="biktarvy-study1489-efficacy"></a>

### How does Biktarvy compare with abacavir/dolutegravir/lamivudine in adults starting HIV treatment (Study 1489)?

> “BIKTARVY vs ABC/DTG/3TC in treatment-naïve adults<sup>1-5</sup>
> Phase 3, Randomized, Double-Blind, Active-Controlled, Noninferiority Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=BIKTARVY%20vs%20ABC%2FDTG%2F3TC%20in%20treatment%2Dna%C3%AFve,Randomized%2C%20Double%2DBlind%2C%20Active%2DControlled%2C%20Noninferiority%20Study)

> “Primary endpoint
>
> Proportion of adults with HIV-1 RNA <50 copies/mL at Week 48 (NI margin 12%) using the FDA snapshot algorithm<sup>5</sup>
>
> Secondary endpoints
>
> Efficacy, safety, and tolerability were assessed through Weeks 96 and 144<sup>3,4</sup>
>
> Open-label extension
>
> Efficacy in the OLE from Week 144 through Week 240 was calculated using missing=excluded (M=E) and missing=failure (M=F) analyses<sup>1,7</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=Primary%20endpoint,missing%3Dexcluded%20%28M%3DE%29%20and%20missing%3Dfailure%20%28M%3DF%29)

> “In Trial 1489, adults were randomized in a 1:1 ratio to receive either BIKTARVY 
> (containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF) (N=314) or 
> ABC/DTG/3TC (600 mg/50 mg/300 mg) (N=315) once daily.”

Source: [BIKTARVY: Prescribing information, page 36, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=36)

> “BIKTARVY was noninferior to ABC/DTG/3TC at Week 144”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=BIKTARVY%20was%20noninferior%20to%20ABC%2FDTG%2F3TC%20at%20Week%20144)

> “Table 14  
> Virologic Outcomes of Randomized Treatment in Trials 1489 and 
> 1490 at Week 144<sup>a</sup> in Adults with No Antiretroviral Treatment History 
>
> Trial 1489 
> Trial 1490 
>
> BIKTARVY  
> (N=314) 
>  ABC/DTG/3TC 
> (N=315) 
> BIKTARVY  
> (N=320) 
>  DTG + FTC/TAF 
> (N=325) 
> HIV-1 RNA < 50 copies/mL  
> 82% 
> 84% 
> 82% 
> 84% 
> Treatment Difference (95% 
> CI) BIKTARVY vs. 
> Comparator 
> -2.6% (-8.5% to 3.4%) 
> -1.9% (-7.8% to 3.9%) 
> HIV-1 RNA ≥ 50 copies/mL<sup>b</sup> 
> 1% 
> 3% 
>  5% 
> 3% 
> No Virologic Data at Week 
> 144 Window 
> 18% 
> 13% 
> 13% 
> 13% 
> Discontinued Study Drug 
> Due to AE or Death<sup>c</sup> 
> 1% 
> 2% 
> 3% 
> 3% 
> Discontinued Study Drug 
> Due to Other Reasons 
> and Last Available HIV-1 
> RNA <50 copies/mL<sup>d</sup> 
> 16% 
> 11% 
> 11% 
> 9% 
> Missing Data During 
> Window but on Study 
> Drug 
> 1% 
> <1% 
> 0% 
> 1% 
> a. Week 144 window was between Day 967 and 1050 (inclusive). 
> b. Includes participants who had ≥ 50 copies/mL in the Week 144 window; participants who discontinued early due 
> to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or 
> lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL. 
> c. Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window 
> if this resulted in no virologic data on treatment during the specified window. 
> d. Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., 
> withdrew consent, loss to follow-up, etc.”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

> “In Trials 1489 and 1490, the mean increase from baseline in CD4+ count at Week 144 
> was 299 and 317 cells per mm<sup>3</sup> in the BIKTARVY and ABC/DTG/3TC groups, 
> respectively, and 278 and 289 cells per mm<sup>3</sup> in the BIKTARVY and DTG + FTC/TAF 
> groups, respectively.”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

> “In a 96-week open-label extension from Week 144 through Week 240, virologic suppression at each study visit through Week 240 was assessed for adults who were initially randomized to BIKTARVY at Week 0<sup>1,7</sup>:
>
> Using an M=E analysis, 97.7% (n=213) maintained virologic suppression at Week 240
> Using an M=F analysis, 66.2% (n=314) maintained virologic suppression at Week 240
>
> Virologic suppression was also assessed in participants who switched from ABC/DTG/3TC to BIKTARVY at Week 144<sup>7</sup>:
>
> Using an M=E analysis, 99.5% (n=218) maintained virologic suppression at Week 240
> Using an M=F analysis, 85.4% (n=254) maintained virologic suppression at Week 240
>
> In an M=E analysis, participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL. In an M=F analysis, all missing data are treated as treatment failures (HIV-1 RNA ≥50 copies/mL).”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=In%20a%2096%2Dweek%20open%2Dlabel%20extension,failures%20%28HIV%2D1%20RNA%20%E2%89%A550%20copies%2FmL%29.)

Note: Each row of Table 14 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490). The Week 48 primary endpoint results appear as charts on the treatment-naive page and are not quoted here.

## Study 1490

<a id="biktarvy-study1490-efficacy"></a>

### How does Biktarvy compare with dolutegravir plus emtricitabine/tenofovir alafenamide in adults starting treatment (Study 1490)?

> “BIKTARVY vs DTG+FTC/TAF in treatment-naïve adults<sup>1,2,4,9,10</sup>
> Phase 3, Randomized, Double-Blind, Active-Controlled, Noninferiority Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=BIKTARVY%20vs%20DTG%2BFTC%2FTAF%20in%20treatment%2Dna%C3%AFve,Randomized%2C%20Double%2DBlind%2C%20Active%2DControlled%2C%20Noninferiority%20Study)

> “In Trial 1490, participants 
> were randomized in a 1:1 ratio to receive either BIKTARVY (N=320) or DTG + FTC/TAF 
> (50 mg + 200 mg/25 mg) (N=325) once daily.”

Source: [BIKTARVY: Prescribing information, page 36, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=36)

> “BIKTARVY was noninferior to DTG+FTC/TAF at Week 144”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=BIKTARVY%20was%20noninferior%20to%20DTG%2BFTC%2FTAF%20at%20Week%20144)

> “Table 14  
> Virologic Outcomes of Randomized Treatment in Trials 1489 and 
> 1490 at Week 144<sup>a</sup> in Adults with No Antiretroviral Treatment History 
>
> Trial 1489 
> Trial 1490 
>
> BIKTARVY  
> (N=314) 
>  ABC/DTG/3TC 
> (N=315) 
> BIKTARVY  
> (N=320) 
>  DTG + FTC/TAF 
> (N=325) 
> HIV-1 RNA < 50 copies/mL  
> 82% 
> 84% 
> 82% 
> 84% 
> Treatment Difference (95% 
> CI) BIKTARVY vs. 
> Comparator 
> -2.6% (-8.5% to 3.4%) 
> -1.9% (-7.8% to 3.9%) 
> HIV-1 RNA ≥ 50 copies/mL<sup>b</sup> 
> 1% 
> 3% 
>  5% 
> 3% 
> No Virologic Data at Week 
> 144 Window 
> 18% 
> 13% 
> 13% 
> 13% 
> Discontinued Study Drug 
> Due to AE or Death<sup>c</sup> 
> 1% 
> 2% 
> 3% 
> 3% 
> Discontinued Study Drug 
> Due to Other Reasons 
> and Last Available HIV-1 
> RNA <50 copies/mL<sup>d</sup> 
> 16% 
> 11% 
> 11% 
> 9% 
> Missing Data During 
> Window but on Study 
> Drug 
> 1% 
> <1% 
> 0% 
> 1% 
> a. Week 144 window was between Day 967 and 1050 (inclusive). 
> b. Includes participants who had ≥ 50 copies/mL in the Week 144 window; participants who discontinued early due 
> to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or 
> lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL. 
> c. Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window 
> if this resulted in no virologic data on treatment during the specified window. 
> d. Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., 
> withdrew consent, loss to follow-up, etc.”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

> “In Trials 1489 and 1490, the mean increase from baseline in CD4+ count at Week 144 
> was 299 and 317 cells per mm<sup>3</sup> in the BIKTARVY and ABC/DTG/3TC groups, 
> respectively, and 278 and 289 cells per mm<sup>3</sup> in the BIKTARVY and DTG + FTC/TAF 
> groups, respectively.”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

> “In a 96-week open-label extension from Week 144 through Week 240, virologic suppression at each study visit through Week 240 was assessed for adults who were initially randomized to BIKTARVY at Week 0<sup>1,7</sup>:
>
> Using an M=E analysis, 99.5% (n=219) maintained virologic suppression at Week 240
> Using an M=F analysis, 68.1% (n=320) maintained virologic suppression at Week 240
>
> Virologic suppression was also assessed in participants who switched from DTG+FTC/TAF to BIKTARVY at Week 144<sup>7</sup>:
>
> Using an M=E analysis, 99.1% (n=234) maintained virologic suppression at Week 240
> Using an M=F analysis, 87.5% (n=265) maintained virologic suppression at Week 240
>
> In an M=E analysis, participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL. In an M=F analysis, all missing data are treated as treatment failures (HIV-1 RNA ≥50 copies/mL).”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=Using%20an%20M%3DE%20analysis%2C%2099.5%25%20%28n%3D219%29,failures%20%28HIV%2D1%20RNA%20%E2%89%A550%20copies%2FmL%29.)

Note: Each row of Table 14 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490). The Week 48 primary endpoint results appear as charts on the treatment-naive page and are not quoted here.

## Treatment-naive subgroups

<a id="biktarvy-high-viral-load-low-cd4"></a>

### Does Biktarvy work when starting treatment with a high viral load or low CD4 count?

> “In a post hoc subgroup analysis of pooled data from Studies 1489 and 1490 through Week 240, participants initially randomized to BIKTARVY were stratified by:
>
> Baseline viral load (BL VL) <100,000, 100,000 to 400,000, and >400,000 copies/mL
> Baseline CD4 < or ≥200 cells/μL
> Baseline viral load ≥100,000 copies/mL and CD4 <200 cells/μL”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=In%20a%20post%20hoc%20subgroup,copies%2FmL%20and%20CD4%20%3C200%20cells%2F%CE%BCL)

> “Virologic suppression was achieved and maintained in all subgroups at 5 years<sup>14</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=Virologic%20suppression%20was%20achieved%20and%20maintained%20in%20all%20subgroups%20at%205)

> “In an M=E analysis, participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/treatment-naive#:~:text=In%20an%20M%3DE%20analysis%2C%20participants%20with%20missing%20data%20are%20excluded%20when%20calculating%20the%20proportion%20of%20participants%20with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL.,-Virologic%20suppression%20was)

> “Treatment outcomes were similar across subgroups by age, sex, race, baseline viral 
> load, and baseline CD4+ cell count.”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

Note: The subgroup suppression rates appear as charts on the treatment-naive page and are not quoted here.

## Resistance

<a id="biktarvy-resistance"></a>

### Has resistance to Biktarvy developed in clinical trials?

> “*Based on the resistance analysis population or final resistance analysis population, as applicable.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/resistance-summary#:~:text=%2ABased%20on%20the%20resistance%20analysis,resistance%20analysis%20population%2C%20as%20applicable.)

> “Among the treatment-naïve adults who participated in Studies 1489 and 1490, 634 participants received BIKTARVY through Week 144 of the double-blind phase, and 1025 participants received BIKTARVY through Week 96 of the extension phase. Of the 1025 treatment-naïve adults who participated in the OLE, 506 participants continued on BIKTARVY, 254 participants switched from ABC/DTG/3TC, and 265 participants switched from DTG+FTC/TAF at Week 144.<sup>1-3</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/resistance-summary#:~:text=Among%20the%20treatment%2Dna%C3%AFve%20adults%20who,switched%20from%20DTG%2BFTC%2FTAF%20at%20Week)

> “In the final resistance analysis population, no amino acid substitutions associated with BIKTARVY resistance emerged in the 11 participants who experienced treatment failure and had evaluable genotypic resistance data.<sup>1</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/resistance-summary#:~:text=In%20the%20final%20resistance%20analysis,and%20had%20evaluable%20genotypic%20resistance)

> “In the final resistance analysis population, no specific amino acid 
> substitutions emerged consistently in the 11 participants with treatment failure and 
> with evaluable genotypic resistance data and failed to establish an association with 
> genotypic BIC resistance. There were no treatment-emergent NRTI resistance-
> associated substitutions detected in the 11 evaluated treatment failure isolates.”

Source: [BIKTARVY: Prescribing information, page 32, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=32)

> “Among 572 virologically suppressed adults randomized to BIKTARVY in Studies 1844 and 1878 through Week 48, 2 participants with virologic rebound had genotypic and phenotypic data (1 for RT, 1 for IN and RT), and no treatment-emergent resistance to BIKTARVY was detected through Week 48.<sup>1,4-6,</sup>*”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/resistance-summary#:~:text=Among%20572%20virologically%20suppressed%20adults,BIKTARVY%20was%20detected%20through%20Week)

<a id="biktarvy-m184v-resistance"></a>

### Does Biktarvy work in virologically suppressed people with the M184V/I mutation who switch to it?

> “47 study participants randomized to BIKTARVY had M184V/I at baseline
>
> 89% (n=42/47) of study participants who switched to BIKTARVY remained virologically suppressed at Week 48<sup>1</sup>
> 11% (n=5/47) of study participants who switched to BIKTARVY did not have virologic data at Week 48<sup>1</sup>
> All study participants with M184V/I at baseline who switched to BIKTARVY and had virologic data at Week 48 remained virologically suppressed (n=42)<sup>1</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=47%20study%20participants%20randomized%20to,Week%2048%20remained%20virologically%20suppressed)

> “31 study participants randomized to BIKTARVY and 20 study participants who switched to BIKTARVY at Week 24 had M184V/I resistance mutation at baseline<sup>25</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=31%20study%20participants%20randomized%20to,had%20M184V%2FI%20resistance%20mutation%20at)

> “All study participants with M184V/I at baseline who switched to BIKTARVY and had virologic data at Week 48 remained virologically suppressed (n=50)<sup>25</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=at%20Week%2024-,All%20study%20participants%20with%20M184V%2FI%20at%20baseline%20who%20switched%20to,Week%2048%20remained%20virologically%20suppressed)

> “A retrospective post hoc pooled analysis of study participant data from 6 BIKTARVY clinical trials<sup>29</sup>:”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=A%20retrospective%20post%20hoc%20pooled,data%20from%206%20BIKTARVY%20clinical)

> “Study participants were virologically suppressed (HIV-1 RNA <50 copies/mL for 3 or 6 months) on a 3-drug regimen<sup>29</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Study%20participants%20were%20virologically%20suppressed,6%20months%29%20on%20a%203%2Ddrug)

> “All participants retrospectively found to have preexisting resistance to any component of BIKTARVY were allowed to continue and were included in efficacy analyses<sup>29</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=All%20participants%20retrospectively%20found%20to,and%20were%20included%20in%20efficacy)

> “Among 2044 virologically suppressed people included in the retrospective post hoc pooled analysis<sup>29,†</sup>:
>
> 7 met the criteria for resistance analysis. No treatment-emergent resistance was detected.<sup>‡</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%202044%20virologically%20suppressed%20people,analysis.%20No%20treatment%2Demergent%20resistance%20was)

> “<sup>§</sup>BIKTARVY is not indicated for patients with known or suspected substitutions associated with resistance to bictegravir or tenofovir.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=is%20not%20indicated%20for%20patients,resistance%20to%20bictegravir%20or%20tenofovir.)

> “Reduced susceptibility to FTC was 
> associated with M184V or I substitutions in HIV-1 RT.”

Source: [BIKTARVY: Prescribing information, page 32, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=32)

> “BIKTARVY is DHHS guidelines–recommended<sup>17,18</sup>
> As an initial regimen for most people living with HIV
> In virologically suppressed people with M184V/I resistance mutation (BIII)*”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=BIKTARVY%20is%20DHHS,with%20M184V%2FI%20resistance%20mutation%20%28BIII%29%2A)

> “*Rating of recommendation: B=Moderate. Rating of evidence: III=Expert opinion.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=%2ARating%20of%20recommendation%3A%20B%3DModerate.%20Rating%20of%20evidence%3A%20III%3DExpert%20opinion.)

Note: The second and third excerpts are from the BRAAVE section of the virologically suppressed page. The pooled virologic response rates appear as charts on that page and are not quoted here.

## Study 1844

<a id="biktarvy-study1844-switch"></a>

### Does Biktarvy keep HIV suppressed after a switch from abacavir/dolutegravir/lamivudine (Study 1844)?

> “In Trial 1844, the efficacy and safety of switching from a regimen of DTG + ABC/3TC or 
> ABC/DTG/3TC to BIKTARVY were evaluated in a randomized, double-blind trial of 
> virologically-suppressed (HIV-1 RNA less than 50 copies per mL) HIV-1 infected adults 
> (N=563, randomized and dosed). Participants must have been stably suppressed (HIV-
> 1 RNA less than 50 copies per mL) on their baseline regimen for at least 3 months prior 
> to trial entry and had no history of treatment failure. Participants were randomized in a 
> 1:1 ratio to either switch to BIKTARVY (containing 50 mg of BIC, 200 mg of FTC, and  
> 25 mg of TAF) at baseline (N=282), or stay on their baseline antiretroviral regimen 
> (N=281). Participants had a mean age of 45 years (range 20–71), 89% were male, 73% 
> were White, and 22% were Black. 17% of participants identified as Hispanic/Latino. The 
> mean baseline CD4+ cell count was 723 cells per mm<sup>3</sup> (range 124–2444).”

Source: [BIKTARVY: Prescribing information, page 38, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=38)

> “Table 15 
> Virologic Outcomes of Trials 1844 and 1878 at Week 48<sup>a</sup> in 
> Virologically-Suppressed Adults who Switched to BIKTARVY 
>
> Trial 1844 
> Trial 1878 
>
> BIKTARVY  
> (N=282) 
> ABC/DTG/3TC 
> (N=281) 
> BIKTARVY  
> (N=290) 
> ATV- or DRV-
> based regimen<sup>b</sup> 
> (N=287) 
> HIV-1 RNA ≥ 50 
> copies/mL<sup>c</sup> 
> 1% 
> <1% 
> 2% 
> 2% 
>       Treatment Difference 
>       (95% CI) 
> 0.7% (-1.0% to 2.8%) 
> 0.0% (-2.5% to 2.5%) 
> HIV-1 RNA < 50 
> copies/mL  
> 94% 
> 95% 
> 92% 
> 89% 
> No Virologic Data at 
> Week 48 Window 
> 5% 
> 5% 
> 6% 
> 9% 
> Discontinued Study 
> Drug Due to AE or 
> Death and Last 
> Available HIV-1 RNA 
> < 50 copies/mL 
> 2% 
> 1% 
> 1% 
> 1% 
> Discontinued Study 
> Drug Due to Other 
> Reasons and Last 
> Available HIV-1 RNA 
> < 50 copies/mL<sup>d</sup> 
> 2% 
> 3% 
> 3% 
> 7% 
> Missing Data During 
> Window but on Study 
> Drug 
> 2% 
> 1% 
> 2% 
> 2% 
> a. 
> Week 48 window was between Day 295 and 378 (inclusive). 
> b. 
> ATV given with cobicistat or ritonavir or DRV given with cobicistat or ritonavir plus either FTC/TDF or ABC/3TC. 
> c. 
> Includes participants who had ≥ 50 copies/mL in the Week 48 window; participants who discontinued early due to 
> lack or loss of efficacy; participants who discontinued for reasons other than lack or loss of efficacy and at the 
> time of discontinuation had a viral value of ≥ 50 copies/mL. 
> d. 
> Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., 
> withdrew consent, loss to follow-up, etc.”

Source: [BIKTARVY: Prescribing information, page 39, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=39)

> “In Trial 1844, treatment outcomes between treatment groups were similar across 
> subgroups by age, sex, race, and region. The mean change from baseline in CD4+ 
> count at Week 48 was -31 cells per mm<sup>3</sup> in participants who switched to BIKTARVY and 
> 4 cells per mm<sup>3</sup> in participants who stayed on ABC/DTG/3TC.”

Source: [BIKTARVY: Prescribing information, page 39, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=39)

> “In a 120-week open-label extension from Week 48, using an M=E analysis, virologic suppression was maintained in 100% of study participants on BIKTARVY (n=14) at Week 168 from BIKTARVY switch.<sup>5</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20a%20120%2Dweek%20open%2Dlabel%20extension,at%20Week%20168%20from%20BIKTARVY)

> “In an M=E analysis, study participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20an%20M%3DE%20analysis%2C%20study,with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL)

> “Study 1844 open-label extension: 524 virologically suppressed adults participated; 259 were continuing BIKTARVY and 265 switched to BIKTARVY at Week 48. No treatment-emergent resistance to BIKTARVY was detected through Week 168, including in the 1 participant who switched to BIKTARVY and met the criteria for resistance analysis.<sup>5,11</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Study%201844%20open%2Dlabel%20extension%3A%20524,met%20the%20criteria%20for%20resistance)

Note: Each row of Table 15 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1844), then BIKTARVY and the ATV- or DRV-based regimen (Trial 1878). Under the M=E analysis, the Week 168 result covers the 14 participants with data at that visit; 524 participants entered the extension.

## Study 1878

<a id="biktarvy-study1878-switch"></a>

### Does Biktarvy keep HIV suppressed after a switch from boosted atazanavir or darunavir (Study 1878)?

> “In Trial 1878, the efficacy and safety of switching from either ABC/3TC or FTC/TDF 
> (200/300 mg) plus ATV or DRV (given with either cobicistat or ritonavir) to BIKTARVY 
> (containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF) were evaluated in a 
> randomized, open-label study of virologically-suppressed HIV-1 infected adults (N=577, 
> randomized and dosed). Participants must have been stably suppressed on their 
> baseline regimen for at least 6 months, must not have been previously treated with any 
> INSTI, and had no history of treatment failure. Participants were randomized in a 1:1 
> ratio to either switch to BIKTARVY (N=290) or stay on their baseline antiretroviral 
> regimen (N=287). Participants had a mean age of 46 years (range 20–79), 83% were 
> male, 66% were White, and 26% were Black. 19% of participants identified as 
> Hispanic/Latino. The mean baseline CD4+ cell count was 663 cells per mm<sup>3</sup> (range 62–
> 2582). Participants were stratified by prior treatment regimen. At screening, 15% of 
> participants were receiving ABC/3TC plus ATV or DRV (given with either cobicistat or 
> ritonavir) and 85% of participants were receiving FTC/TDF plus ATV or DRV (given with 
> either cobicistat or ritonavir).”

Source: [BIKTARVY: Prescribing information, page 38, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=38)

> “Table 15 
> Virologic Outcomes of Trials 1844 and 1878 at Week 48<sup>a</sup> in 
> Virologically-Suppressed Adults who Switched to BIKTARVY 
>
> Trial 1844 
> Trial 1878 
>
> BIKTARVY  
> (N=282) 
> ABC/DTG/3TC 
> (N=281) 
> BIKTARVY  
> (N=290) 
> ATV- or DRV-
> based regimen<sup>b</sup> 
> (N=287) 
> HIV-1 RNA ≥ 50 
> copies/mL<sup>c</sup> 
> 1% 
> <1% 
> 2% 
> 2% 
>       Treatment Difference 
>       (95% CI) 
> 0.7% (-1.0% to 2.8%) 
> 0.0% (-2.5% to 2.5%) 
> HIV-1 RNA < 50 
> copies/mL  
> 94% 
> 95% 
> 92% 
> 89% 
> No Virologic Data at 
> Week 48 Window 
> 5% 
> 5% 
> 6% 
> 9% 
> Discontinued Study 
> Drug Due to AE or 
> Death and Last 
> Available HIV-1 RNA 
> < 50 copies/mL 
> 2% 
> 1% 
> 1% 
> 1% 
> Discontinued Study 
> Drug Due to Other 
> Reasons and Last 
> Available HIV-1 RNA 
> < 50 copies/mL<sup>d</sup> 
> 2% 
> 3% 
> 3% 
> 7% 
> Missing Data During 
> Window but on Study 
> Drug 
> 2% 
> 1% 
> 2% 
> 2% 
> a. 
> Week 48 window was between Day 295 and 378 (inclusive). 
> b. 
> ATV given with cobicistat or ritonavir or DRV given with cobicistat or ritonavir plus either FTC/TDF or ABC/3TC. 
> c. 
> Includes participants who had ≥ 50 copies/mL in the Week 48 window; participants who discontinued early due to 
> lack or loss of efficacy; participants who discontinued for reasons other than lack or loss of efficacy and at the 
> time of discontinuation had a viral value of ≥ 50 copies/mL. 
> d. 
> Includes participants who discontinued for reasons other than an AE, death, or lack or loss of efficacy, e.g., 
> withdrew consent, loss to follow-up, etc.”

Source: [BIKTARVY: Prescribing information, page 39, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=39)

> “In Trial 1878, treatment outcomes between treatment groups were similar across 
> subgroups by age, sex, race, and region. The mean change from baseline in CD4+ 
> count at Week 48 was 25 cells per mm<sup>3</sup> in patients who switched to BIKTARVY and 0 
> cells per mm<sup>3</sup> in patients who stayed on their baseline regimen.”

Source: [BIKTARVY: Prescribing information, page 39, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=39)

> “In the extension from Week 48, using an M=E analysis, virologic suppression was maintained in 100% of study participants on BIKTARVY (n=318) at Week 96 from BIKTARVY switch.<sup>8</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20the%20extension%20from%20Week,at%20Week%2096%20from%20BIKTARVY)

> “In an M=E analysis, participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20an%20M%3DE%20analysis%2C%20participants,with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL)

> “Study 1878 extension: 516 virologically suppressed adults participated; 272 were continuing BIKTARVY and 244 switched to BIKTARVY at Week 48. No treatment-emergent resistance to BIKTARVY was detected through Week 96, including in the 3 participants who switched to BIKTARVY and met the criteria for resistance analysis.<sup>8,12</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Study%201878%20extension%3A%20516%20virologically,met%20the%20criteria%20for%20resistance)

Note: Each row of Table 15 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1844), then BIKTARVY and the ATV- or DRV-based regimen (Trial 1878).

## Study 4030

<a id="biktarvy-study4030-switch"></a>

### Does Biktarvy keep HIV suppressed after a switch from dolutegravir plus emtricitabine/tenofovir alafenamide (Study 4030)?

> “BIKTARVY vs DTG+FTC/TAF in virologically suppressed adults with HIV, including those with NRTI resistance<sup>1,13</sup>
> Phase 3, Randomized, Double-Blind, Active-Controlled Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=BIKTARVY%20vs%20DTG%2BFTC%2FTAF%20in%20virologically,3%2C%20Randomized%2C%20Double%2DBlind%2C%20Active%2DControlled%20Study)

> “Primary endpoint
>
> Proportion of adults with HIV-1 RNA ≥50 copies/mL at Week 48 (NI margin 4%) using FDA snapshot algorithm<sup>13</sup>
>
> Secondary endpoint
>
> Proportion of adults with HIV-1 RNA <50 copies/mL at Week 48 (NI margin 10%) using FDA snapshot algorithm<sup>13</sup>
>
> Study design randomization
>
> Randomization was stratified by NRTI backbone at screening (FTC/TAF vs FTC/TDF) and documented or suspected history of NRTI resistance.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Secondary%20endpoint,suspected%20history%20of%20NRTI%20resistance.)

> “In Trial 4030, the efficacy and safety of switching from DTG plus either FTC/TAF or 
> FTC/TDF to BIKTARVY (containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF) 
> were evaluated in a randomized, double-blind study of virologically suppressed HIV-1 
> infected adults. Participants must have been stably suppressed (HIV-1 RNA less than 
> 50 copies/mL) on their baseline regimen for at least 6 months (if documented or”

Source: [BIKTARVY: Prescribing information, page 39, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=39)

> “suspected NRTI resistance), or at least 3 months (if no documented or suspected NRTI 
> resistance) prior to trial entry. Participants were randomized to  switch to BIKTARVY 
> (N=284) or to continue their prior treatment regimen, DTG+ F/TAF (N=281). The primary 
> endpoint was the proportion of participants with HIV-1 RNA > 50 copies/mL at Week 48. 
> At Week 48 the proportion of participants with HIV-1 RNA ≥50 copies/mL was 0.4% 
> (1/284) in the BIKTARVY group and 1.1% (3/281) in the DTG+F/TAF group (difference -
> 0.7% [95%CI: -2.8%, 1.0%]).  
> Of the participants receiving BIKTARVY, 47 had HIV-1 with pre-existing M184V or I 
> resistance substitutions (M184M/V, M184M/I, M184V/I, M184V) in HIV-1 RT. Eighty-
> nine percent (42/47) of participants with M184V or I remained suppressed (HIV-1 RNA < 
> 50 copies/mL) and 11% (5/47 participants) did not have virologic data at the Week 48 
> timepoint due to study drug discontinuation.”

Source: [BIKTARVY: Prescribing information, page 40, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=40)

> “93% of adults who switched to BIKTARVY maintained virologic suppression at Week 48<sup>13</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=93%25%20of%20adults%20who%20switched%20to%20BIKTARVY%20maintained%20virologic%20suppression%20at%20Week)

> “Among the 284 virologically suppressed adults randomized to BIKTARVY in Study 4030 through Week 48, 0 participants met the criteria for resistance analysis, and no treatment-emergent resistance to BIKTARVY was detected through Week 48.<sup>13</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%20the%20284%20virologically%20suppressed,BIKTARVY%20was%20detected%20through%20Week)

## Study 1961

<a id="biktarvy-study1961-women"></a>

### Is switching to Biktarvy effective in virologically suppressed women (Study 1961)?

> “BIKTARVY vs an INSTI- or PI-based regimen in virologically suppressed adult women<sup>2,15</sup>
> Phase 3, Randomized, Open-Label, Active-Controlled Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=BIKTARVY%20vs%20an%20INSTI%2D%20or,3%2C%20Randomized%2C%20Open%2DLabel%2C%20Active%2DControlled%20Study)

> “Primary endpoint
>
> Proportion of participants with HIV-1 RNA ≥50 copies/mL at Week 48 (NI margin 4%) using the FDA snapshot algorithm<sup>15</sup>
>
> Extension phase
>
> The objective of the extension phase from Week 48 through Week 96 was to evaluate the efficacy and safety of BIKTARVY after additional exposure<sup>2</sup>
>
> At Week 48, the women receiving an INSTI- or PI-based regimen at baseline were switched to BIKTARVY, and an additional analysis was performed at Week 96
> Efficacy in the extension phase from Week 48 through Week 96 was calculated using a missing=excluded (M=E) analysis”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Proportion%20of%20participants%20with%20HIV%2D1%20RNA%20%E2%89%A550,using%20a%20missing%3Dexcluded%20%28M%3DE%29%20analysis)

> “<sup>†</sup>E/C/F/TAF or E/C/F/TDF or ATV+RTV+FTC/TDF.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=or%20E%2FC%2FF%2FTDF%20or%20ATV%2BRTV%2BFTC%2FTDF.)

> “In a 48-week extension phase from Week 48, using an M=E analysis, virologic suppression was maintained at Week 96 in 99.5% of participants who stayed on BIKTARVY (n=208) and 98.5% of participants who switched to BIKTARVY (n=194) at Week 48.<sup>2</sup>
>
> In an M=E analysis, participants with missing data are excluded when calculating the proportion of study participants with HIV-1 RNA <50 copies/mL”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20a%2048%2Dweek%20extension%20phase,with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL)

> “Among 234 virologically suppressed adult women randomized to BIKTARVY in Study 1961 through Week 48<sup>15</sup>:
>
> 1 participant met the criteria for resistance analysis
> No treatment-emergent resistance to BIKTARVY was detected through Week 48
>
> 459 virologically suppressed adult women participated in the extension phase of Study 1961. 231 of them continued on BIKTARVY and 228 switched to BIKTARVY at Week 48<sup>2</sup>:
>
> No treatment-emergent resistance to BIKTARVY was detected through Week 96, including in the 3 participants who switched to BIKTARVY and met the criteria for resistance analysis”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%20234%20virologically%20suppressed%20adult,and%20met%20the%20criteria%20for%20resistance%20analysis)

Note: The Week 48 virologic response rates appear as a chart on the virologically suppressed page and are not quoted here.

## Study 4449

<a id="biktarvy-study4449-older-adults"></a>

### Is switching to Biktarvy effective in adults aged 65 and older (Study 4449)?

> “BIKTARVY in virologically suppressed adults aged ≥65 years<sup>1,17,18</sup>
> Phase 3b, Open-Label, Single-Arm Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=BIKTARVY%20in%20virologically%20suppressed%20adults,Phase%203b%2C%20Open%2DLabel%2C%20Single%2DArm%20Study)

> “Primary endpoint
>
> Proportion of participants with HIV-1 RNA <50 copies/mL at Week 24 using the FDA snapshot algorithm<sup>17</sup>
>
> Secondary endpoints
> Efficacy at Weeks 48, 72, and 96 using the FDA snapshot algorithm<sup>18</sup>
> Safety and tolerability through Week 96<sup>18</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Proportion%20of%20participants%20with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL%20at,Safety%20and%20tolerability%20through%20Week)

> “In Trial 4449, the efficacy and safety of switching from a stable antiretroviral regimen to 
> BIKTARVY (containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF) were 
> evaluated in an open-label, single arm trial of virologically-suppressed (HIV-1 RNA less 
> than 50 copies per mL) HIV-1 infected adults aged 65 years and over (N=86). 
> Participants treated with BIKTARVY had a mean age of 70 years (range: 65 to 80). The 
> primary endpoint was the proportion of participants with HIV RNA > 50 copies/mL at 
> Week 48. No participants had HIV RNA > 50 copies/mL. Ninety-one percent (78/86) of 
> participants remained suppressed (HIV-1 RNA < 50 copies/mL) at Week 48. Eight 
> participants did not have virologic data at the Week 48 timepoint due to discontinuation 
> or missing data.”

Source: [BIKTARVY: Prescribing information, page 40, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=40)

> “At Week 96, 11 study participants did not have data due to the COVID-19 pandemic and restrictions on clinic/study visits. All were suppressed at their last visit.<sup>18</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=At%20Week%2096%2C%2011%20study,were%20suppressed%20at%20their%20last)

> “Among 86 virologically suppressed adults aged ≥65 years in Study 4449 through Week 96<sup>17,18,§</sup>:
>
> No treatment-emergent resistance to BIKTARVY was detected through Week 96. No participants met the criteria for resistance analysis”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%2086%20virologically%20suppressed%20adults,the%20criteria%20for%20resistance%20analysis)

Note: The site states the primary endpoint as HIV-1 RNA <50 copies/mL at Week 24; the prescribing information states it as HIV RNA >50 copies/mL at Week 48.

## Study 1474

<a id="biktarvy-study1474-children"></a>

### Is switching to Biktarvy effective in virologically suppressed children and adolescents (Study 1474)?

> “BIKTARVY in virologically suppressed children and adolescents<sup>1,21,22</sup>
> Phase 2/3, Single-Arm, Open-Label, Multi-Cohort Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=BIKTARVY%20in%20virologically%20suppressed%20children,2%2F3%2C%20Single%2DArm%2C%20Open%2DLabel%2C%20Multi%2DCohort%20Study)

> “*Cohort 3 received low-dose BIKTARVY (bictegravir 30 mg, emtricitabine 120 mg, tenofovir alafenamide 15 mg).
>
> Primary endpoint
>
> Determination of plasma PK and evaluation of safety and tolerability through Week 24<sup>1,21,22</sup>
>
> Secondary endpoints
>
> Proportion of children and adolescents with HIV-1 RNA <50 copies/mL at Week 24 using the FDA snapshot algorithm<sup>22</sup>
>
> Efficacy, safety, and tolerability were also evaluated at Week 48
> Extension phase (cohorts 1 & 2)
>
> Efficacy in the extension phase from Week 48 to Week 96 was calculated using missing=excluded (M=E) and missing=failure (M=F) analyses<sup>22</sup>
>
> Safety and tolerability were also evaluated through Week 96”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=%2ACohort%203%20received%20low%2Ddose%20BIKTARVY,also%20evaluated%20through%20Week%2096)

> “In Trial 1474, an open-label, single arm trial the efficacy, safety, and pharmacokinetics 
> of BIKTARVY in pediatric participants with HIV-1 were evaluated in virologically-
> suppressed adolescents between the ages of 12 to less than 18 years weighing at least 
> 35 kg (N=50), in virologically-suppressed children between the ages of 6 to less than 12 
> years weighing at least 25 kg (N=50), and in virologically-suppressed children at least 2 
> years of age and weighing at least 14 to less than 25 kg (N=22).”

Source: [BIKTARVY: Prescribing information, page 40, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=40)

> “After switching to BIKTARVY, 98% (49/50) of participants in cohort 1 remained 
> suppressed (HIV-1 RNA < 50 copies/mL) at Week 48.”

Source: [BIKTARVY: Prescribing information, page 41, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=41)

> “After switching to BIKTARVY (containing 50 mg of BIC, 200 mg of FTC, and 25 mg of 
> TAF), 100% (50/50) of participants in cohort 2 remained suppressed (HIV-1 RNA < 50 
> copies/mL) at Week 24.”

Source: [BIKTARVY: Prescribing information, page 41, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=41)

> “After switching to BIKTARVY, 91% (20/22) of participants in cohort 3 remained 
> suppressed (HIV-1 RNA < 50 copies/mL) at Week 24. HIV-1 RNA was not collected at 
> Week 24 for 2 participants because of COVID-19 pandemic-related study disruption.”

Source: [BIKTARVY: Prescribing information, page 41, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=41)

> “In the extension from Week 48, using an M=E analysis, 99% of children and adolescents (n=96) maintained virologic suppression at Week 96. Using an M=F analysis, 95% (n=100) maintained virologic suppression at Week 96.
>
> In an M=E analysis, study participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL. In an M=F analysis, all missing data are treated as treatment failures (HIV-1 RNA ≥50 copies/mL).”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=at%20Week%2096.-,In%20an%20M%3DE%20analysis%2C%20study%20participants%20with%20missing%20data%20are,failures%20%28HIV%2D1%20RNA%20%E2%89%A550%20copies%2FmL%29.)

> “Among 100 virologically suppressed children and adolescents aged >6 to <18 years in Study 1474 (cohorts 1 & 2)<sup>1,12,21,22</sup>:
>
> One participant met criteria for resistance analysis. No treatment-emergent resistance to BIKTARVY was detected through Week 96
>
> Among 22 virologically suppressed children aged ≥2 (weighing ≥14 kg to <25 kg) in Study 1474 (cohort 3)<sup>1,22,24</sup>:
>
> No treatment-emergent resistance to BIKTARVY was detected through Week 48. No participants met the criteria for resistance analysis”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%20100%20virologically%20suppressed%20children,the%20criteria%20for%20resistance%20analysis)

## BRAAVE

<a id="biktarvy-braave-black-adults"></a>

### Is switching to Biktarvy effective in Black American adults (BRAAVE)?

> “BIKTARVY vs stable baseline regimen in virologically suppressed Black Americans<sup>3,25,26</sup>
> Randomized Phase 3b, Multicenter, Open-Label Study”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=BIKTARVY%20vs%20stable%20baseline%20regimen,Phase%203b%2C%20Multicenter%2C%20Open%2DLabel%20Study)

> “Primary endpoint
>
> Proportion of adults with HIV-1 RNA ≥50 copies/mL at Week 24 (NI margin 6%) using the FDA snapshot algorithm<sup>25,26</sup>
>
> Secondary endpoints
> Proportion of adults with HIV-1 RNA ≥50 copies/mL at Week 48 using the FDA snapshot algorithm<sup>25</sup>
> Proportion of adults with HIV-1 RNA <50 copies/mL at Weeks 24 and 48<sup>25</sup>
> Extension phase
>
> The objective of the extension phase from Week 48 to Week 72 was to evaluate the efficacy and safety of switching to BIKTARVY after additional exposure<sup>3</sup>
>
> COVID-19 Operational Impact: Some visits between Week 48 and Week 72 were virtual due to the COVID-19 pandemic”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Secondary%20endpoints-,Proportion%20of%20adults%20with%20HIV%2D1%20RNA%20%E2%89%A550%20copies%2FmL%20at%20Week,due%20to%20the%20COVID%2D19%20pandemic)

> “Switching to BIKTARVY in Black Americans was noninferior to staying on a baseline regimen at Week 24”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Switching%20to%20BIKTARVY%20in%20Black,baseline%20regimen%20at%20Week%2024)

> “In a 24-week extension from Week 48 through Week 72 using an M=E analysis, virologic suppression was maintained at Week 72 in 99% of participants who stayed on BIKTARVY (n=248) and 100% of participants who switched to BIKTARVY (n=127) at Week 24.<sup>3</sup>
>
> In an M=E analysis, participants with missing data are excluded when calculating the proportion of participants with HIV-1 RNA <50 copies/mL”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=In%20a%2024%2Dweek%20extension%20from,with%20HIV%2D1%20RNA%20%3C50%20copies%2FmL)

> “Among 330 virologically suppressed adults randomized to BIKTARVY in BRAAVE through Week 24, 1 participant met criteria for resistance analysis and no treatment-emergent resistance to BIKTARVY was detected through Week 24.<sup>25</sup>
>
> At Week 24, 320 participants continued BIKTARVY and 163 switched to BIKTARVY. Of these participants, 469 participants completed the study drug or chose to remain in the extension phase at Week 48. No additional participant was analyzed for resistance, and no treatment-emergent resistance to BIKTARVY was detected through Week 72.<sup>3,25,28</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/virologically-suppressed#:~:text=Among%20330%20virologically%20suppressed%20adults,and%20no%20treatment%2Demergent%20resistance%20to%20BIKTARVY%20was%20detected%20through%20Week)

Note: The Week 24 virologic response rates appear as a chart on the virologically suppressed page and are not quoted here.

## Comparative studies

<a id="biktarvy-dyad-vs-dovato"></a>

### Biktarvy vs Dovato (dolutegravir/lamivudine): what did the DYAD study show?

> “A phase 4, single-center, open-label, noninferiority study, sponsored by ViiV Healthcare, that  
> randomized 222 virologically suppressed adults (HIV-1 RNA <50 copies/mL) with no prior virologic  
> failure (2:1) to switch to DOVATO (n=149) or continue on BIKTARVY (n=73)”

Source: [BIKTARVY: Explore now, page 2, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=2)

> “Proportion of participants with HIV-1 RNA ≥50 copies/mL at Week 48 using the FDA snapshot  
> algorithm (ITT-E), 6% noninferiority margin”

Source: [BIKTARVY: Explore now, page 2, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=2)

> “Primary endpoint was met at Week 48: 4% in the DOVATO arm (n=6) and 7% in the BIKTARVY arm (n=5) 
> had HIV-1 RNA ≥50 copies/mL (treatment difference, -2.8%; 95% CI, −11.4% to 3.1%)”

Source: [BIKTARVY: Explore now, page 2, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=2)

> “Safety and tolerability, including adverse events, renal markers, lipids, and weight, were summarized 
> using descriptive statistics. The clinical significance of these findings is unknown”

Source: [BIKTARVY: Explore now, page 2, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=2)

Note: In DYAD, participants on BIKTARVY were randomized to switch to DOVATO or to continue BIKTARVY.

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
